Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

被引：0
作者：
Peng Yuan
Jianzhong Shentu
Jianming Xu
Wendy Burke
Kate Hsu
Maria Learoyd
Min Zhu
Binghe Xu
机构：
[1] Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC),National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center
[2] The First Affiliated Hospital of Zhejiang University,Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease
[3] Academy of Military Medical Sciences,Affiliated Hospital Cancer Center, The 307th Hospital of Chinese People’s Liberation Army
[4] Covance Clinical Research Unit,undefined
[5] AstraZeneca,undefined
[6] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Chinese patients; Olaparib; Paclitaxel; PARP inhibitor; Pharmacokinetics; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：963 / 974
页数：11
相关论文
共 285 条
[71]  
Qin S(undefined)undefined undefined undefined undefined-undefined
[72]  
Xu N(undefined)undefined undefined undefined undefined-undefined
[73]  
Im SA(undefined)undefined undefined undefined undefined-undefined
[74]  
Locker G(undefined)undefined undefined undefined undefined-undefined
[75]  
Rowe P(undefined)undefined undefined undefined undefined-undefined
[76]  
Shi X(undefined)undefined undefined undefined undefined-undefined
[77]  
Hodgson D(undefined)undefined undefined undefined undefined-undefined
[78]  
Liu YZ(undefined)undefined undefined undefined undefined-undefined
[79]  
Boku N(undefined)undefined undefined undefined undefined-undefined
[80]  
Balmana J(undefined)undefined undefined undefined undefined-undefined
3456789101112